| Study |
Reference |
|
Bane - ACEs/ARB (Controls unexposed sick), 2024
|
Bane Antihypertensive Medication Use before and during Pregnancy and the Risk of Severe Maternal Morbidity in Individuals with Prepregnancy Hypertension. Am J Perinatol 2024; 41:e728-e738
|
|
Bateman - ACE inhibitor (Controls unexposed, NOS), 2017
|
Bateman Angiotensin-Converting Enzyme Inhibitors and the Risk of Congenital Malformations. Obstet Gynecol 2017; 129:174-184 Bateman, B.T. ACE inhibitors during the first trimester of pregnancy and the risk of congenital malformations: A cohort study Pharmacoepidemiol. Drug Saf. 2015; 24:400-.
|
|
Bateman - ACE inhibitor (Controls unexposed, sick), 2017
|
Bateman Angiotensin-Converting Enzyme Inhibitors and the Risk of Congenital Malformations. Obstet Gynecol 2017; 129:174-184 Bateman, B.T. ACE inhibitors during the first trimester of pregnancy and the risk of congenital malformations: A cohort study Pharmacoepidemiol. Drug Saf. 2015; 24:400-.
|
|
Caton - Renin inhibitors (ACE/ARBs), 2009
|
Caton Antihypertensive medication use during pregnancy and the risk of cardiovascular malformations. Hypertension 2009; 54:63-70
|
|
Chintamaneni - ACE inhibitors, 2018
|
Chintamaneni, S. Exposure to angiotensin-converting enzyme inhibitors in pregnancy and the risk of low birth weight and congenital cardiac malformation J. Am. Coll. Cardiol. 2018; 71:NP37-.
|
|
Colvin - ACEi, 2014
|
Colvin The use of angiotensin converting enzyme inhibitors during the first trimester of pregnancy. J Pharmacovigil. 2014;2(3).
|
|
Cooper - ACEi, 2006
|
Cooper Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006; 354:2443-51
|
|
Cournot - ACEi, 2006
|
Cournot Angiotensin-converting enzyme (ACE) inhibitors during first trimester of pregnancy: a French prospective collaborative study Drug Safety 2006; 29:927.
|
|
Diav-Citrin - ACEi/ARB, 2011
|
Diav-Citrin O Pregnancy outcome after in utero exposure to angiotensin converting enzyme inhibitors or angiotensin receptor blockers. Reprod Toxicol 2011;31:540-5
|
|
Fisher - Renin inhibitors (ACE/ARBs) (Controls unexposed, disease free), 2017
|
Fisher Maternal Antihypertensive Medication Use and Congenital Heart Defects: Updated Results From the National Birth Defects Prevention Study. Hypertension 2017; 69:798-805
|
|
Fisher - Renin inhibitors (ACE/ARBs) (Controls unexposed, sick), 2017
|
Fisher Maternal Antihypertensive Medication Use and Congenital Heart Defects: Updated Results From the National Birth Defects Prevention Study. Hypertension 2017; 69:798-805
|
|
Fisher a - Renin-angiotensin system blockers, 2018
|
Fisher Maternal antihypertensive medication use and selected birth defects in the National Birth Defects Prevention Study. Birth Defects Res 2018; 110:1433-1442
|
|
Fisher b - ACE inhibitors (Controls unexposed, disease free), 2018
|
Fisher Maternal Hypertension, Antihypertensive Medication Use, and Small for Gestational Age Births in the National Birth Defects Prevention Study, 1997-2011. Matern Child Health J 2018; 22:237-246
|
|
Fisher b - ACE inhibitors (Controls unexposed, sick), 2018
|
Fisher Maternal Hypertension, Antihypertensive Medication Use, and Small for Gestational Age Births in the National Birth Defects Prevention Study, 1997-2011. Matern Child Health J 2018; 22:237-246
|
|
Hoeltzenbein a - ARBs, 2018
|
Hoeltzenbein Pregnancy outcome after first trimester use of angiotensin AT1 receptor blockers: an observational cohort study. Clin Res Cardiol 2018; 107:679-687
|
|
Hoeltzenbein b - ACEi, 2018
|
Hoeltzenbein Increased rate of birth defects after first trimester use of angiotensin converting enzyme inhibitors - Treatment or hypertension related? An observational cohort study. Pregnancy Hypertens 2018; 13:65-71
|
|
Lennestal - ACE inhibitors, 2009
|
Lennestal Maternal use of antihypertensive drugs in early pregnancy and delivery outcome, notably the presence of congenital heart defects in the infants. Eur J Clin Pharmacol 2009; 65:615-25
|
|
Li - ACE inhibitors (Controls unexposed, disease free), 2011
|
Li DK Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring: a retrospective cohort study. BMJ 2011;343:d5931
|
|
Li - ACE inhibitors (Controls unexposed, sick), 2011
|
Li DK Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring: a retrospective cohort study. BMJ 2011;343:d5931
|
|
Malm - ACEi, 2008
|
Malm First trimester use of ACE-inhibitors and risk of major malformations. Reprod Toxicol. 2008;26(1):67.
|
|
Moretti - ACEi/ARBs, 2012
|
Moretti The Fetal Safety of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers. Obstet Gynecol Int 2012; 2012:658310
|
|
Nakhai-Pour - ACE inhibitors, 2010
|
Nakhai-Pour Antihypertensive medication use during pregnancy and the risk of major congenital malformations or small-for-gestational-age newborns. Birth Defects Res B Dev Reprod Toxicol 2010; 89:147-54
|
|
Vaclavik - ACEs/ARBs, 2024
|
Vaclavik, J. MATERNAL AND FETAL OUTCOMES OF VARIOUS ANTIHYPERTENSIVE TREATMENT REGIMENS DURING PREGNANCY: INSIGHTS FROM THE CZECH NATIONAL REGISTRY 2012-2022 Int. J. Hypertens. 2024; 42:e10-.
|
|
Van der Zande - ACE-Is and/or ARBs, 2024
|
van der Zande ACE Inhibitor and Angiotensin Receptor Blocker Use During Pregnancy: Data From the ESC Registry Of Pregnancy and Cardiac Disease (ROPAC). Am J Cardiol 2024; 230:27-36
|
|
Van Gelder - ACE inhibitors, 2015
|
van Gelder MM Maternal hypertensive disorders, antihypertensive medication use, and the risk of birth defects: a case-control study. BJOG 2015;122:1002-9
|
|
Van Zutphen - Renin–angiotensin system-acting, 2014
|
Caton Maternal hypertension, antihypertensive medication use, and the risk of severe hypospadias. Birth Defects Res A Clin Mol Teratol 2008; 82:34-40 Van Zutphen AR Maternal hypertension, medication use, and hypospadias in the National Birth Defects Prevention Study. Obstet Gynecol 2014;123:309-17
|
|
Vasilakis-Scaramozza - ACE inhibitors, 2013
|
Vasilakis-Scaramozza Antihypertensive drugs and the risk of congenital anomalies. Pharmacotherapy 2013; 33:476-82
|
